Renalytix Plc (RENX) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Rentalytics conference call to review fourth quarter and full year fiscal 2023 financial results. At this time, all participants are in a listen only mode. We will be facilitating a question and answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DiNardo of Capcom Partners for a few introductory comments. Please go ahead. Thank you, Michelle, and thank you all for participating in today's call. Joining me today from Reno Lake Spread Formal Marks are James McCullough, Chief Executive Officer, Tom McClain, President, and James Sterling, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Private Securities Legislation Reform Act of 1995. Any statements made during this call that relate to expectations or predictions of future results and events or performance are forward-looking statements. Examples of these statements include, without limitation, the potential benefits, including economic savings of kidney intellect, the commercial prospects of Kidney Intellects, including whether Kidney Intellects will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of Kidney Intellects to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes, friends in our market and potential benefits of government policy change, the impact of COVID-19 at other world events in our business, our expectations for hiring, product development, strategic partnerships and collaborations, reimburseme...